


## JNJ-26489112

<b>Cat. No.:</b>	HY-12596
<b>CAS No.:</b>	871824-55-4
<b>Molecular Formula:</b>	C <sub>9</sub> H <sub>11</sub> ClN <sub>2</sub> O <sub>4</sub> S
<b>Molecular Weight:</b>	278.71
<b>Target:</b>	Calcium Channel; Sodium Channel; Potassium Channel
<b>Pathway:</b>	Membrane Transporter/Ion Channel; Neuronal Signaling
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	JNJ-26489112, a CNS-active agent, exhibits broad-spectrum anticonvulsant activity in rodents against audiogenic, electrically-induced, and chemically-induced seizures. JNJ-26489112 inhibits voltage-gated Na <sup>+</sup> channels and N-type Ca <sup>2+</sup> channels, and is effective as a K <sup>+</sup> channel opener. JNJ-26489112 has very weak inhibition of CA-II (IC <sub>50</sub> =35 μM) and CA-I (18 μM) <sup>[1]</sup> .
<b>In Vitro</b>	JNJ-26489112 inhibits calcium influx in response to depolarization (fluorescence-based assay) with an IC <sub>50</sub> of 34 μM. In a whole-cell, patch-clamp experiment with low-frequency stimulation (0.07 Hz), intended to measure N-type channel activity directly, JNJ-26489112 causes a concentration-dependent increase in inhibition, with an IC <sub>50</sub> of 70 μM. JNJ-26489112 is a KCNQ2 channel opener, particularly at -50 mV <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	JNJ-26489112 (i.p.) effectively blocks chemically-induced, forelimb clonic seizures in mice ( male CF-1 albino mice) that are caused by subcutaneous bicuculine (Bic), picrotoxin (Pic), or pentylenetetrazol (PTZ), with 1-h ED50 values of 197, 189, or 109 mg/kg, respectively <sup>[1]</sup> . In adult male rats, JNJ-26489112 (p.o; 10 mg/kg) treatment shows the C <sub>max</sub> , t <sub>max</sub> , F, t <sub>1/2</sub> , and AUC (total exposure) values in plasma were 9090 ng/mL (33 μM), 53 min, 95%, 8.2 h, and 53,200 ng-h/mL. Linear, dose-related increases in exposure were observed at 10, 30, and 300 mg/kg. JNJ-26489112 (i.v.; 2 mg/kg) treatment shows the V <sub>dss</sub> is 390 mL/kg and the CL is 96 mL/h-kg. In female beagle dogs, JNJ-26489112 (p.o; 10 mg/kg) treatment shows the C <sub>max</sub> , t <sub>max</sub> , F, t <sub>1/2</sub> , and AUC values in plasma are 11,500 ng/mL (41 μM), 55 min, 83%, 20 h, and 212,000 ng-h/mL. . JNJ-26489112 (i.v.; 2 mg/kg) treatment shows the the V <sub>dss</sub> and CL values are 630 mL/kg and 30 mL/h-kg, respectively <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. McComsey DF, et al. Novel, broad-spectrum anticonvulsants containing a sulfamide group: pharmacological properties of (S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112). J Med Chem. 2013;56(22):9019-9030.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA